Literature DB >> 8235617

Multifactorial nature of human immunodeficiency virus disease: implications for therapy.

A S Fauci1.   

Abstract

The immunopathogenic mechanisms underlying human immunodeficiency virus (HIV) disease are extremely complex; the disease process is multifactorial with multiple overlapping phases. Viral burden is substantial and viral replication occurs throughout the entire course of HIV infection. Inappropriate immune activation and elevated secretion of certain cytokines compound the pathogenic process. Profound immunosuppression ultimately occurs together with a disruption of the microenvironment of the immune system, which is probably unable to regenerate spontaneously. Thus, therapeutic strategies in HIV disease must not be unidimensional, but rather must be linked to the complex pathogenic components of the disease and must address where feasible each of the recognized pathogenic processes for the possibility of therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8235617     DOI: 10.1126/science.8235617

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  185 in total

1.  Human immunodeficiency virus type 1 induces apoptosis in CD4(+) but not in CD8(+) T cells in ex vivo-infected human lymphoid tissue.

Authors:  J C Grivel; N Malkevitch; L Margolis
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Tat protein induces self-perpetuating permissivity for productive HIV-1 infection.

Authors:  C J Li; Y Ueda; B Shi; L Borodyansky; L Huang; Y Z Li; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection.

Authors:  Z Q Zhang; T Schuler; W Cavert; D W Notermans; K Gebhard; K Henry; D V Havlir; H F Günthard; J K Wong; S Little; M B Feinberg; M A Polis; L K Schrager; T W Schacker; D D Richman; L Corey; S A Danner; A T Haase
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  The NIH Clinical Center and the future of clinical research.

Authors:  John I Gallin
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

Review 5.  The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer.

Authors:  Frances Mercer; Derya Unutmaz
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

6.  Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor.

Authors:  David J Auerbach; Yin Lin; Huiyi Miao; Raffaello Cimbro; Michelle J Difiore; Monica E Gianolini; Lucinda Furci; Priscilla Biswas; Anthony S Fauci; Paolo Lusso
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

7.  T-cell-receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function.

Authors:  B Liang; S Ardestani; J J Marchalonis; R R Watson
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

8.  Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression.

Authors:  A L Kinter; S M Bende; E C Hardy; R Jackson; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.

Authors:  O J Cohen; G Pantaleo; M Holodniy; S Schnittman; M Niu; C Graziosi; G N Pavlakis; J Lalezari; J A Bartlett; R T Steigbigel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

10.  In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals.

Authors:  Y Sasaki; A Blanchard; H L Watson; S Garcia; A Dulioust; L Montagnier; M L Gougeon
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.